Welcome to our dedicated page for Enanta Pharmaceuticals SEC filings (Ticker: ENTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enanta Pharmaceuticals, Inc. filings document a clinical-stage biotechnology issuer focused on small-molecule therapies for viral infections and immunological diseases. Its Form 8-K disclosures cover financial results, Regulation FD clinical-data materials, research and development updates, material agreements and capital-structure information for common stock traded under ENTA on the Nasdaq Global Select Market.
Proxy and annual meeting filings record governance matters including director elections, advisory executive compensation votes, auditor ratification and amendments to the 2019 Equity Incentive Plan. Other event disclosures also document patent litigation matters, including proceedings involving U.S. Patent No. 11,358,953 and Pfizer's COVID-19 antiviral Paxlovid.
Enanta Pharmaceuticals Inc. (ENTA) reported a new equity award to its President and CEO, who also serves as a director. On November 25, 2025, the insider received a stock option to purchase 310,000 shares of Enanta common stock at an exercise price of $13.66 per share, expiring on November 25, 2035.
The option is scheduled to become exercisable in substantially equal quarterly installments over four years from the grant date, subject to the optionholder’s continued employment. Following this grant, the reporting person beneficially owns 310,000 derivative securities directly in the form of this stock option.
Enanta Pharmaceuticals, Inc. (ENTA) files its annual report describing a virology- and immunology-focused biotech business built on small-molecule drug discovery. The company already earns double-digit royalties from AbbVie’s HCV regimen MAVYRET/MAVIRET, driven by Enanta’s protease inhibitor glecaprevir, and has received $954 million in cumulative royalties through September 30, 2025. In April 2023 it sold 54.5% of future MAVYRET/MAVIRET royalties through June 2032 to an OMERS affiliate for $200 million, subject to a 1.42x cap.
Enanta reports $188.9 million in cash, cash equivalents and short-term marketable securities as of September 30, 2025 and expects, together with retained HCV royalties and proceeds from an October 2025 equity offering, to fund operations into fiscal 2029. The pipeline is wholly owned and includes two clinical RSV antivirals (zelicapavir and EDP‑323) with positive Phase 2 data, plus preclinical oral programs targeting KIT (EDP‑978) for chronic spontaneous urticaria and STAT6 (EPS‑3903) for atopic dermatitis and other type 2 inflammatory diseases. Management warns that revenue is highly dependent on AbbVie’s HCV sales and that significant additional funding will be required if programs advance as planned.
Enanta Pharmaceuticals, Inc. (ENTA) filed a current report to announce that it released a press release with its financial results for the fiscal quarter and year ended September 30, 2025. The press release, dated November 17, 2025, is included as Exhibit 99.1 and is incorporated by reference, meaning the detailed numbers and commentary are contained in that exhibit rather than in the body of this report. This filing is a standard earnings disclosure under Item 2.02 of the Exchange Act.
Deep Track entities and David Kroin filed a Schedule 13G disclosing shared beneficial ownership of 1,484,513 shares of Enanta Pharmaceuticals common stock, representing 5.33% of the class based on 27,877,923 shares outstanding. The filing shows shared voting and shared dispositive power over those shares, with no sole voting or dispositive power reported. The holders state the position was not acquired to change or influence control and the filing is a joint filing by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin.
Enanta Pharmaceuticals reported a material event in an 8-K that discloses an Underwriting Agreement dated September 30, 2025, legal opinion and consent from Foley Hoag LLP, and an embedded interactive cover page XBRL file. The filing restates standard forward-looking statement disclaimers and indicates the company will not update forward-looking statements except as required by law. The document is signed by Jay R. Luly, Ph.D., President and Chief Executive Officer, with a filing date of October 1, 2025.
Enanta Pharmaceuticals (ENTA) prospectus supplement describes a securities offering that would issue shares at $10.00 per share with aggregate proceeds shown as $65,000,000 (and an underwriting fee example of $0.60 per share or $3,900,000). Net proceeds are intended to fund clinical trials, research and development, working capital and general corporate purposes. The filing highlights ongoing revenue from an AbbVie collaboration and a 2023 royalty sale that help fund Enanta’s R&D programs. Clinical programs discussed include oral STAT6 inhibitors (a development candidate expected to be nominated in the second half of 2025), zelicapavir safety data showing mostly mild adverse events, and disease burdens for RSV and COVID-19 with specific hospitalization and mortality ranges for RSV in older adults. The supplement details a 60-day lock-up for insiders, exceptions (including Rule 10b5-1 plans), tax withholding rules for non-U.S. holders (generally 30% on dividends absent treaty relief), and references to incorporated reports and underwriting disclosures.
Enanta Pharmaceuticals (ENTA) prospectus supplement excerpts describe an offering with underwriter arrangements, lock-up agreements and planned use of proceeds to fund clinical trials, research and general corporate purposes. The company notes ongoing royalties from an AbbVie collaboration and proceeds from an April 2023 royalty sale that support its R&D programs.
The filing highlights clinical and preclinical programs including a STAT6 oral inhibitor program with a development candidate expected to be nominated in the second half of 2025, zelicapavir safety outcomes (mostly mild AEs; diarrhea 3.3%, asthma 2.5%) and antiviral efficacy signals versus placebo. The supplement also summarizes U.S. federal tax withholding rules for non-U.S. holders and customary risk and forward-looking statement disclaimers.
Enanta Pharmaceuticals (ENTA) prospectus supplement excerpts describe an offering with underwriter arrangements, lock-up agreements and planned use of proceeds to fund clinical trials, research and general corporate purposes. The company notes ongoing royalties from an AbbVie collaboration and proceeds from an April 2023 royalty sale that support its R&D programs.
The filing highlights clinical and preclinical programs including a STAT6 oral inhibitor program with a development candidate expected to be nominated in the second half of 2025, zelicapavir safety outcomes (mostly mild AEs; diarrhea 3.3%, asthma 2.5%) and antiviral efficacy signals versus placebo. The supplement also summarizes U.S. federal tax withholding rules for non-U.S. holders and customary risk and forward-looking statement disclaimers.
Enanta Pharmaceuticals reported that it has positive topline results from a Phase 2b study of its drug candidate zelicapavir (formerly EDP-938) in high-risk adults with respiratory syncytial virus (RSV). This mid-stage trial focuses on adults who are more likely to develop serious RSV disease, so encouraging data at this stage can be important for deciding whether to move the program into later-stage studies.
To share more detail, the company prepared a slide deck titled “Phase 2b Study of Zelicapavir in High-Risk Adults: RSVHR Topline Results,” which is included as an exhibit to this report. The presentation is being furnished rather than filed, which limits how it is treated under certain securities law liability provisions, but it provides investors with an overview of the initial clinical findings for zelicapavir in RSV.
Enanta Pharmaceuticals filed an Form 8-K reporting a proof-of-concept, signal-finding study of oral antiviral zelicapavir for RSV. Patients were enrolled within 72 hours of symptom onset and received 800mg once daily for 5 days or placebo. The trial measured symptoms using the RiiQTM scale covering 13 RSV symptoms and assessed a four-symptom lower respiratory tract disease (LRTD) subset as the primary endpoint, defined as time to resolution to mild, with predefined complete-resolution analyses also conducted. Secondary measures included total RiiQTM score, patient global impressions, virology, safety, and hospitalization rate. The filing references the company’s 2024 10-K and includes the company caution on forward-looking statements. The 8-K is signed by Jay R. Luly, Ph.D. and dated September 29, 2025.
Enanta Pharmaceuticals (ENTA) Form 3: Kathleen S. Capps reports beneficial ownership tied to her role as Executive Director, Accounting & Controller and director/officer of Enanta. She directly holds 5,829 shares represented by unvested RSUs and a series of stock options exercisable between 04/01/2026 and 11/27/2034 covering named share amounts. The filing lists vesting schedules for RSUs and exercise prices for each option.